Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587341 | 0.92 | PRMT6 (0.50) | PRMT6P2RY12LMNAADORA1 | |
| SCHEMBL29665041 | 0.90 | P2RY12 (0.51) | PRMT6P2RY12P2RY2P2RY1P2RY6 | |
| SCHEMBL16587338 | 0.88 | P2RY12 (0.48) | PRMT6P2RY12 | |
| SCHEMBL18490431 | 0.88 | PRMT6 (0.47) | PRMT6P2RY12BMPR1B | |
| SCHEMBL21384881 | 0.87 | PRMT6 (0.47) | PRMT6P2RY12LMNAP2RY2P2RY1 | |
| SCHEMBL13396713 | 0.84 | PRMT6 (0.51) | PRMT6P2RY12LMNAP2RY2P2RY1 | |
| SCHEMBL9850107 | 0.83 | LMNA (0.56) | PRMT6P2RY12LMNAP2RY2P2RY1 | |
| SCHEMBL9850105 | 0.83 | LMNA (0.56) | PRMT6P2RY12LMNAP2RY2P2RY1 | |
| SCHEMBL13975682 | 0.83 | LMNA (0.56) | PRMT6P2RY12LMNAP2RY2P2RY1 | |
| SCHEMBL29881768 | 0.83 | PRMT6 (0.42) | PRMT6P2RY12LMNAP2RY2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340379-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9296779-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150203525-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2015-07-23 | — | — | US | disclosed |
| US-8987437-B2 | Processes and intermediates for preparing anti-HIV Agents | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203525-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | PRMT6 1631/4885P2RY12 3946/4885LMNA 1511/4885 |
| US-20160340379-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | PRMT6 1631/4885P2RY12 3946/4885LMNA 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.